Thus, EPHA2 is a potentially powerful biomarker for poor prognosis and progression of breast cancer, and targeting exosomal EPHA2-AMPK signaling may serve as a potential strategy for breast cancer therapy. Here, EPHA2 is linked to breast carcinoma.